Siloam Semanggi - Mochtar Riady Comprehensive Cancer Center (MRCCC) Siloam Semanggi again presents the leading oncology scientific forum in Indonesia through The 6th Siloam Oncology Summit 2026. This activity will be held on May 22-24, 2026 at the Shangri-La Hotel Jakarta. Siloam Oncology Summit 2026 emphasizes the role of MRCCC Siloam Semanggi as a leading cancer center.
Siloam Oncology Summit 2026 confirms the commitment of MRCCC Siloam Semanggi in providing personalized cancer care based on multidisciplinary collaboration and global knowledge exchange, as well as strengthening capacity building through applied training to accelerate diagnosis and therapy decisions.
Supported by MRCCC Siloam Semanggi's experience in handling more than 15,000 patients per month as well as the utilization of cutting-edge technology, this initiative is expected to expand access to more accurate and patient-centered cancer services.
Under the global theme "United by Unique" from the Union for International Cancer Control (UICC) 2025-2027, The 6th Siloam Oncology Summit 2026 presents an approach to cancer that focuses on the individualization of therapy, by integrating advances in precision oncology, modern radiotherapy, and the Multidisciplinary Team (MDT) approach.
Executive Director of MRCCC Siloam Semanggi, dr. Edy Gunawan, MARS, explained, "Through the Siloam Oncology Summit 2026, we hope to strengthen multidisciplinary collaboration and bridge global expertise with clinical practices in Indonesia."
"We believe that the future of cancer treatment lies in an increasingly personalized, precise, and team-based approach, so that each patient can obtain the most appropriate and quality therapy", continued dr. Edy.
Siloam Oncology Summit 2026 presents various scientific sessions, ranging from a series of 4 plenary sessions on the second and third days, 11 interactive workshop sessions over three days, and 24 symposium sessions on the second and third days. Then a scientific poster competition featuring 30+ posters including Original Research, Case Report, Systematic Review, and Meta-analysis categories, with topics ranging from diagnostics, therapy, to palliative care.
Based on the Global Cancer Observatory (GLOBOCAN) 2022, there were approximately 408,661 new cases and 242,099 deaths due to cancer in Indonesia. The most common types of cancer are breast, cervical, lung, and colorectal. More than 60-70% of cancer patients in Indonesia are diagnosed at an advanced stage. This condition emphasizes the low awareness of the public for early detection, as well as the need to strengthen the referral system and integrated cancer treatment.
In the context of therapy, radiotherapy is one of the main pillars of cancer treatment that continues to develop, including through the use of CT-LINAC (Computed Tomography Linear Accelerator) technology which allows real-time visualization of tumors and adjustment of therapy with high precision. This approach is in line with the focus on precision oncology raised in the Siloam Oncology Summit 2026, namely adaptive therapy and centered on patient characteristics.
The workshop and plenary sessions will highlight the role of Integrated CT-LINAC in supporting adaptive radiotherapy. This innovation not only improves accuracy and efficiency, but also emphasizes the importance of multidisciplinary collaboration in designing therapy in real-time, resulting in more accurate and patient-centered treatment.
Siloam Oncology Summit 2026 will present more than 11 international speakers from leading health institutions in the world, as well as more than 93 national speakers. As the largest multidisciplinary oncology conference in Indonesia, Siloam Oncology Summit 2026 invites various international experts from various global health institutions. Among others from The University of Texas MD Anderson Cancer Center, United States; Australia Private Hospitals Network (APHN), Australia; National University Hospital, Singapore; Sun Yat-sen University Cancer Center, China; Asan Medical Center, Republic of Korea; Rajavithi Hospital, Thailand; Yonsei Medical Center, Republic of Korea; The Netherlands Cancer Institute (AVL/NKI), The Netherlands; Sir Run Run Shaw Hospital, China; University of Tsukuba, Japan; and University of Genoa, Italy. This collaboration confirms the role of MRCCC Siloam Semanggi in encouraging the transfer of knowledge and the application of global best practices in Indonesia.
Dr. Edy Gunawan, MARS, emphasized, "Siloam Oncology Summit 2026 is a manifestation of the commitment of MRCCC Siloam Semanggi to strengthen Indonesia's position in the global oncology landscape. Through collaboration with international and national experts, we encourage the implementation of a personalized and multidisciplinary approach in cancer treatment, as well as accelerating the adoption of clinical innovations that are relevant to practice in Indonesia."
The topics discussed this year include modern radiotherapy technology such as Integrated CT-LINAC, as well as Multidisciplinary Team (MDT) in cancer treatment. In addition, there are the latest developments in breast cancer treatment, lung cancer, Hematology Malignancy or blood cancer, Gynecology Oncology or cancer in the female reproductive system, Gastrointestinal Oncology or cancer in the digestive system, and other cancers. Then, the development of Oncology Pharmacy or the role of pharmacy in cancer treatment, Oncology Nursing or medical nurses specializing in cancer, and Supportive Care which includes palliative care are also explained.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
